| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Joan Cid | Q42774397 |
| P2093 | author name string | Pereira A | |
| Campos A | |||
| Peña F | |||
| Sanz C | |||
| Alvarez-Larrán A | |||
| Ramírez C | |||
| Albo C | |||
| Del Río J | |||
| Muncunill J | |||
| Sastre JL | |||
| P2860 | cites work | Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura | Q33328894 |
| Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome | Q33331123 | ||
| Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. | Q33338940 | ||
| Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura | Q33343048 | ||
| ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients | Q33346954 | ||
| Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution | Q33364030 | ||
| High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients | Q33455054 | ||
| Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange | Q33488854 | ||
| Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura | Q33496995 | ||
| SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available | Q33504054 | ||
| von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome | Q33504463 | ||
| Viral inactivation of fresh frozen plasma | Q33992794 | ||
| Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma. | Q50500906 | ||
| Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. | Q50502006 | ||
| The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. | Q50770247 | ||
| Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization | Q50951982 | ||
| THROMBOTIC THROMBOCYTOPENIC PURPURA | Q56286858 | ||
| Completely converting a national blood supply to the use of safer plasma | Q57723066 | ||
| P433 | issue | 4 | |
| P921 | main subject | thrombocytopenia | Q585285 |
| P304 | page(s) | 246-251 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Vox Sanguinis | Q15708866 |
| P1476 | title | Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura | |
| P478 | volume | 86 |
| Q50473987 | A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. |
| Q37776318 | A comparison of methods of pathogen inactivation of FFP |
| Q30441694 | A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura |
| Q33436241 | A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy. |
| Q54712502 | Apheresis activity in Spain: a survey of the Spanish Apheresis Group. |
| Q37606107 | Clinical trials for pathogen reduction in transfusion medicine: a review |
| Q46978173 | Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen |
| Q34310415 | Component pathogen inactivation: a critical review |
| Q33376161 | Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura |
| Q85304336 | Efficacy and safety of plasma exchange: ann 11-year single-center experience of 2730 procedures in 317 patients |
| Q37201179 | Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma? |
| Q26741073 | Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use |
| Q33395696 | Investigational drugs in thrombotic thrombocytopenic purpura. |
| Q33396311 | Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction |
| Q96813845 | Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data |
| Q33401173 | Plasma components: properties, differences, and uses |
| Q104063169 | Plasma exchange and thrombotic microangiopathies: From pathophysiology to clinical practice |
| Q37026225 | Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies |
| Q46423794 | Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments |
| Q37209117 | Recommendations for the transfusion of plasma and platelets |
| Q37062415 | Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma |
| Q33863382 | Role of Riboflavin- and UV Light-Treated Plasma in Prevention of Transfusion-Related Acute Lung Injury |
| Q33370956 | Treatment of thrombotic thrombocytopenic purpura. |
| Q33418125 | Trends in the diagnosis and management of TTP: European perspective |
| Q33424405 | Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study. |
| Q36578184 | Update on pathogen reduction technology for therapeutic plasma: an overview |
| Q38109665 | Update on the use of pathogen-reduced human plasma and platelet concentrates |
| Q37166900 | Updates on pathogen inactivation of plasma using Theraflex methylene blue system |
| Q37789774 | Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period |
| Q90281463 | When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP |
Search more.